Dactolisib
Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor. It also inhibits mTOR. It is being investigated as a possible cancer treatment. It has been shown to be toxic to Waldenström's macroglobulinemia cells. It was the first PI3K inhibitor to enter clinical trials, in 2006 (primary outcome results due in 2010).
Wikipage redirect
primaryTopic
Dactolisib
Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor. It also inhibits mTOR. It is being investigated as a possible cancer treatment. It has been shown to be toxic to Waldenström's macroglobulinemia cells. It was the first PI3K inhibitor to enter clinical trials, in 2006 (primary outcome results due in 2010).
has abstract
Dactolisib (codenamed NVP-BEZ2 ...... outcome results due in 2010).
@en
IUPAC name
2-Methyl-2-{4-[3-methyl-2-oxo- ...... lin-1-yl]phenyl}propanenitrile
@en
thumbnail
Wikipage page ID
28,540,537
Wikipage revision ID
730,166,119
ImageAlt
Ball-and-stick model of the BEZ235 molecule
ImageFile
othernames
NVP-BEZ235; BEZ-235
Verifiedfields
verifiedrevid
458,976,997
Watchedfields
comment
Dactolisib (codenamed NVP-BEZ2 ...... outcome results due in 2010).
@en
label
Dactolisib
@en